The Splicing Efficiency of Activating HRAS Mutations Can Determine Costello Syndrome Phenotype and Frequency in Cancer
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Splicing Efficiency of Activating HRAS Mutations Can Determine Costello Syndrome Phenotype and Frequency in Cancer
Authors
Keywords
Mutation, Sequence motif analysis, Small interfering RNAs, Transfection, Carcinogenesis, RNA extraction, Oligonucleotides, Cancer treatment
Journal
PLoS Genetics
Volume 12, Issue 5, Pages e1006039
Publisher
Public Library of Science (PLoS)
Online
2016-05-20
DOI
10.1371/journal.pgen.1006039
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition
- (2015) Eunhee Kim et al. CANCER CELL
- Antisense oligonucleotide–mediated MDM4 exon 6 skipping impairs tumor growth
- (2015) Michael Dewaele et al. JOURNAL OF CLINICAL INVESTIGATION
- Synonymous Mutations Frequently Act as Driver Mutations in Human Cancers
- (2014) Fran Supek et al. CELL
- TheETFDHc.158A>G Variation Disrupts the Balanced Interplay of ESE- and ESS-Binding Proteins thereby Causing Missplicing and Multiple Acyl-CoA Dehydrogenation Deficiency
- (2013) Rikke K. J. Olsen et al. HUMAN MUTATION
- Dual Role of G-runs and hnRNP F in the Regulation of a Mutation-Activated Pseudoexon in the Fibrinogen Gamma-Chain Transcript
- (2013) Valeria Rimoldi et al. PLoS One
- Contributions of intrinsic mutation rate and selfish selection to levels of de novo HRAS mutations in the paternal germline
- (2013) E. Giannoulatou et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Neonatal lethal Costello syndrome and unusual dinucleotide deletion/insertion mutations in HRAS predicting p.Gly12Val
- (2012) Emma M.M. Burkitt-Wright et al. AMERICAN JOURNAL OF MEDICAL GENETICS PART A
- Two cases with severe lethal course of Costello syndrome associated with HRAS p.G12C and p.G12D
- (2012) Sybille Lorenz et al. European Journal of Medical Genetics
- SRp20 is a proto-oncogene critical for cell proliferation and tumor induction and maintenance
- (2012) Rong Jia et al. International Journal of Biological Sciences
- The splicing factor SRSF6 is amplified and is an oncoprotein in lung and colon cancers
- (2012) Michal Cohen-Eliav et al. JOURNAL OF PATHOLOGY
- hnRNP A1 and hnRNP F Modulate the Alternative Splicing of Exon 11 of the Insulin Receptor Gene
- (2011) Indrani Talukdar et al. PLoS One
- Antitumorigenic potential of STAT3 alternative splicing modulation
- (2011) F. Zammarchi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A rational nomenclature for serine/arginine-rich protein splicing factors (SR proteins)
- (2010) J. L. Manley et al. GENES & DEVELOPMENT
- The phenylalanine hydroxylase c.30C>G synonymous variation (p.G10G) creates a common exonic splicing silencer
- (2010) Steven F. Dobrowolski et al. MOLECULAR GENETICS AND METABOLISM
- Anti-tumor activity of splice-switching oligonucleotides
- (2010) John A. Bauman et al. NUCLEIC ACIDS RESEARCH
- hnRNP H enhances skipping of a nonfunctional exon P3A in CHRNA1 and a mutation disrupting its binding causes congenital myasthenic syndrome
- (2008) A. Masuda et al. HUMAN MOLECULAR GENETICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started